Biotech Values

[jq1234]

Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, or Adalimumab Versus Placebo in Patients with Rheumatoid Arthritis on Background Methotrexate: A Phase 3 Study

[Tofactinib vs Adalimumab data in ACR abstract look good.]

Background/Purpose: Tofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This 12-month (Mo) study (NCT00853385) compared the efficacy and safety of tofacitinib and an active comparator, adalimumab (ADA), vs placebo (PBO) in pts with active RA with inadequate response to methotrexate (MTX).



http://acr.confex.com/acr/2011/webprogram/Paper19572.html